ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

 Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company’s Phase 1b trial of PMN310 in patients with early Alzheimer’s disease (AD), including zero cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all participants and genotypes, including APOE4 homozygotes. Observed early, directionally consistent declines in two complementary biomarkers, plasma pTau217 and CSF MTBR-tau243, […]